PARP1 and triple-negative breast carcinoma: The potent in vitro activity aligns with high affinity for DNMT-1 and HDM2, targets critical for PC3 survival. The affinity to PARP1 will reverse especially, BRCA1/BRCA2-mutated triple-negative breast cancer (TNBC) (Dilmac and Ozpolat, 2023)